Forest Laboratories and Nycomed Receive Complete Response Letter for Roflumilast
- Details
- Category: Product
Forest Laboratories, Inc. (NYSE: FRX) and Nycomed announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for roflumilast.
Bayer Schering Pharma Enhances U.S. Research Strategy with New Innovation Center
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany, will establish a U.S. Innovation Center in San Francisco, Calif. with the goal to expand its global research network and build its specialty pharmaceutical pipeline.
Positive pivotal results on escitalopram in Japan
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) announced that the results from the pivotal study with escitalopram in Japan have been received. The results are positive and according to expectations.
Covex S.A. creates 2000 jobs with the onset of a new agroindustrial project in Latin America
- Details
- Category: Business
Covex S.A., leader in the manufacture of products aimed at improving cerebral functions, successfully reaches the first stage of its introduction in Latin America, as it begins to harvest medicinal plants on an industrial scale, for the onset of its new agroindustrial expansion.
Bayer receives approval for its new oral contraceptive in the U.S.
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany, has received approval from The U.S. entity of Food and Drug Administration (FDA) for its new Natazia® (estradiol valerate/ dienogest) pill for the prevention of pregnancy.
RA.com Features Interactive Resource to Help People Living with Rheumatoid Arthritis
- Details
- Category: Abbott
As any do-it-yourselfer knows, a good home improvement project has both style and substance, adding functionality with aesthetic appeal. For people with rheumatoid arthritis (RA) who may face difficulties around the house, adaptable options around the home are particularly important.
New study results on Dulcolax® confirm efficacy and safety
- Details
- Category: Boehringer Ingelheim
In a clinical study Boehringer Ingelheim recently conducted, Dulcolax® tablets with the active ingredient bisacodyl clearly demonstrated efficacy by increasing the frequency and regularity of bowel movements.
More Pharma News ...
- GSK extends presence in Asia with new strategic alliance in South Korea
- Merck Positioned to Drive Growth Through Innovative Portfolio, Pipeline and Strategy
- Abbott licenses 24 Zydus pharmaceutical products for 15 high-growth emerging markets
- GSK Statement on FDA Advisory Committee meeting on Rotavirus vaccines
- EDUCARE (EDUcation for Cancer in African REgions) Project
- Bayer Schering Pharma Initiates Phase III Trial of Regorafenib
- Bayer Schering Pharma Initiates Phase III Trial of Regorafenib (BAY 73-4506)